Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

Summary

The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet Derived Growth Factor Receptor (PDGFR) amplification. This study is designed to test the hypothesis that patients with malignant gliomas with PDGFR amplification are sensitive to PDGFR kinase inhibitors.

Timeline

Start

2010-04-21

Primary completion

2016-10-05

Completion

2019-01

Publications

• Piccioni D, Juarez TM, Kesari SL, Rose L, Nomura N, Kesari S. Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas. Neurooncol Adv. 2025 Jul 10;7(1):vdaf150. doi: 10.1093/noajnl/vdaf150. eCollection 2025 Jan-Dec.

Drugs

Indications